Evidence map›Paper›PMID 33238591›Full record

ArticleLife (Basel, Switzerland)2020

Prognostic Role of

Ekaterina Blinova, Anton Buzdin, Dmitry Enikeev, Dmitry Roshchin, Maria Suntsova, Elena Samyshina, Aleksey Drobyshev, Olga Deryabina, Tatiana Demura, Dmitry Blinov and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Ekaterina BlinovaDepartment of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia.
Anton BuzdinLaboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia.
Dmitry EnikeevDepartment of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia.
Dmitry RoshchinDepartment of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia.
Maria SuntsovaLaboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia.
Elena SamyshinaLaboratory of Molecular Pharmacology and Drug Design, All-Union Research Center for Biological Active Compounds Safety, 142450 Staraja Kupavna, Russia.
Aleksey DrobyshevLaboratory of Bioinformatics, Institute for Personalized Medicine, Sechenov University, 119991 Moscow, Russia.
Olga DeryabinaDepartment of Oncology, Laboratory of Pharmacology, National Research Ogarev Mordovia State University, 430005 Saransk, Russia.
Tatiana DemuraDepartment of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia.
Dmitry BlinovLaboratory of Molecular Pharmacology and Drug Design, All-Union Research Center for Biological Active Compounds Safety, 142450 Staraja Kupavna, Russia.ORCID 0000-0002-8385-4356
Evgenia ShichDepartment of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia.
Haydar BarakatDepartment of Propaedeutics of Dental Diseases, People's Friendship University of Russia, 117198 Moscow, Russia.
Pieter BorgerLaboratory of the Swiss Hepato-Pancreato-Biliary and Transplantation Center, Department of Surgery, University Hospital Zürich, 8091 Zurich, Switzerland.
Dmitrij MerinovDepartment of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia.
Aleksandr KachmazovDepartment of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia.
Stanislav SerebrianyiDepartment of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia.
Oxana TumutolovaDepartment of Oncology, Laboratory of Pharmacology, National Research Ogarev Mordovia State University, 430005 Saransk, Russia.
Natalia PotoldykovaDepartment of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia.
Pavel ZhdanovDepartment of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia.
Vagarshak GrigoryanDepartment of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia.
Dmitrij PerepechinDepartment of Oncological Urology, Russian National Research Center of Radiology, 125284 Moscow, Russia.
Sechenov University · RUNational Research Mordovia State University · RUPeoples' Friendship University of Russia · RU

Funding

Russian academic excellence project "5-100" for Sechenov First Moscow State Medical University 1/15
6 · The paper itself

Abstract

backgroundbladder cancer is one of the most common urinary tract malignancies. Establishment of robust predictors of disease progression and outcome is important for personalizing treatment of non-muscular invasive bladder carcinoma (NMIBC). In this study we evaluated association of PD-L1 expression with other prognostic biomarkers, such as expression of miRNA-145 and miRNA-200a,

methodstwenty patients with primary luminal NMIBC were enrolled in the study. Tumor grade and risk level were determined in accordance with European Organization for Research and Treatment of Cancer (EORTC) guidelines and World Health Organization (WHO) classification. Neoplasm molecular subtype and PD-L1 expression level were assessed by immunohistochemistry. We used real-time PCR to evaluate the expression of microRNAs and

resultshigh grade primary luminal NMIBC showed comparatively higher expression of PD-L1 and microRNA-145 than a low grade tumor, whereas the latter had a higher

conclusionstumor grade in association with PD-L1 and

Indexed as

cancer progressionexpressionfibroblast growth factor receptor 3microRNAmutationnon-muscular invasive bladder carcinomaPD-L1prognosistumor relapse

Identifiers

PMID33238591
PMCPMC7700587
OpenAlexW3109768616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.